InvestorsHub Logo
Followers 58
Posts 1635
Boards Moderated 0
Alias Born 11/14/2012

Re: None

Tuesday, 08/11/2015 7:07:04 PM

Tuesday, August 11, 2015 7:07:04 PM

Post# of 39
Global Blood Therapeutics, an early-stage biotech developing a small molecule therapy for sickle cell disease, raised $120 million by offering 6.0 million shares at $20, above the range of $16 to $18. Global Blood Therapeutics plans to list on the Nasdaq under the symbol GBT. Morgan Stanley and Goldman Sachs acted as lead managers on the deal.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y